PIK3CA and glioblastoma: A genomic landscape investigation of GBM samples carried out by The Cancer Genome Atlas (TCGA) consortium in over 500 tumor samples revealed that the aberrant activation of PI3K/AKT, TP53 or RB signaling pathways are correlated with treatment response or survival (10).